PCMA Statement on Trump Administration’s Biosimilar Announcement

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement following the Trump Administration’s biosimilar announcement. “America’s pharmacy benefit managers (PBMs) commend the Trump Administration’s dedication to lowering prescription drug costs. Today’s announcement to remove the unnecessary step of providing studies for biosimilar interchangeability is a watershed moment for making biosimilars more […]